Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 20/20 | 0.72 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17653322 | 0.85 | AAK1 (0.72) | AAK1CHEK1GSK3BMKNK1BMP2K | |
| SCHEMBL17653135 | 0.84 | AAK1 (1.00) | AAK1CHEK1GSK3BMKNK1BMP2K | |
| SCHEMBL17653207 | 0.82 | AAK1 (0.69) | AAK1CHEK1GSK3BMKNK1BMP2K | |
| SCHEMBL17653122 | 0.81 | AAK1 (0.67) | AAK1CHEK1GSK3BMKNK1BMP2K | |
| SCHEMBL17653208 | 0.81 | AAK1 (0.66) | AAK1CHEK1GSK3BMKNK1BMP2K | |
| SCHEMBL17653272 | 0.80 | AAK1 (0.65) | AAK1CHEK1GSK3BMKNK1BMP2K | |
| SCHEMBL17653179 | 0.78 | AAK1 (0.62) | AAK1CHEK1GSK3BMKNK1BMP2K | |
| SCHEMBL19253017 | 0.78 | AAK1 (0.62) | AAK1CHEK1GSK3BMKNK1BMP2K | |
| SCHEMBL17653267 | 0.78 | AAK1 (0.62) | AAK1CHEK1GSK3BMKNK1BMP2K | |
| SCHEMBL17653311 | 0.76 | AAK1 (0.60) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-24 | — | — | US | disclosed |
| EP-3200797-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016053794-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016053794-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | AAK1, ULK1, NCK1 | AAK1 1/4885CHEK1 176/4885GSK3B 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.